Trial Profile

Imlifidase in ANCA-associated vasculitis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 31 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imlifidase (Primary)
Indications Adult respiratory distress syndrome; Anti-neutrophil cytoplasmic antibody-associated vasculitis; Microscopic polyangiitis; Pulmonary haemorrhage
Focus Pharmacodynamics
Acronyms ImlifidARDSe

Most Recent Events

02 Feb 2024 According to Hansa Biopharma AB media release, 3 of 10 targeted patients enrolled in this study.
26 Oct 2023 According to Hansa Biopharma AB media release, as of October 26, three patients have been treated with imlifidase.
20 Jul 2023 According to Hansa Biopharma media release, this led by Dr. Adrian Schreiber and Dr. Philipp Enghard, at Charite - Universitatsmedizin Berlin.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com